Tractor Supply Reinstated at Neutral by BofA as Discretionary Headwinds Limit Upside

Bank of America reinstated coverage of Tractor Supply (TSCO) with a Neutral rating and a $47 price target. Q4 2025 comparable store sales rose only +0.3% while operating income fell 6.48% YoY; shares are down ~12% YTD and trade around $44. FY2026 diluted EPS guidance is $2.13–$2.23 versus FY2025 actual $2.06, and BofA cites tariff exposure, SG&A deleverage and weak discretionary demand as key downside risks. The company’s 17 consecutive years of dividend increases and domestic sourcing (~89%) provide a defensive foundation, but catalysts for meaningful EPS upside are absent.

Analysis

Tariff and assortment dynamics are the hidden margins story here: a concentrated 10–12% import exposure maps into a handful of discretionary SKUs (seasonal garden, pet accessories) where price elasticity is highest, so incremental tariff moves will compress gross margin faster than headline sales indicate. Rapid store rollouts create a dichotomy — long‑run unit economics improve with scale, but in the 6–18 month window each new unit dilutes SG&A leverage and elevates markdown risk on discretionary inventory, amplifying quarter‑to‑quarter EPS volatility. Online pet pharmacy (Allivet) is the most important second‑order effect — it shifts revenue composition toward recurring, higher‑margin prescriptions but requires time and marketing investment to convert in‑store customers, so margin benefits are back‑loaded over 12–24 months. Competitive spillovers favor national omnichannel players for routine pet spend and big‑ticket garden/lawn items while local independents capture share on immediate rural needs, setting up a cross‑sector dispersion in retail returns if consumer caution persists.

Key risks are asymmetric: near term (days–quarters) the big tail risk is tariff escalation or a pronounced spending retrenchment that forces deeper markdowns and inventory write‑downs; medium term (3–12 months) the make‑or‑break catalyst is whether Allivet can scale acquisition cost‑effectively and whether comp trends normalize as big‑ticket demand recovers. A faster resolution of tariff exposure or an observable inflection in pet health spending would materially re‑rate consensus, but expect at least two consecutive quarters of margin/data points before conviction. Watch three signals over the next 6 months — gross margin ex‑tariff, Allivet customer acquisition cost and retention, and comp‑store trend in big‑ticket categories — as the most reliable leading indicators of EPS trajectory.

The consensus overlooks timing optionality: the market is pricing much of the structural upside as long‑dated and uncertain, which creates asymmetric option‑like trades. If management can show sequential improvement in Allivet ARPU and a flattening of SG&A per store inside 12 months, upside is compressed into a short window and would produce sharp multiple expansion; conversely, continued tariff pressure will force rational downside. For portfolio construction, treat TSCO as a volatility/transition play — short to neutral near term, selectively long duration exposure via cheap, long‑dated options if you want to play the integration upside without taking full equity risk.

Key Decisions for Investors

• Bearish options spread on TSCO (6–9 months): buy the $40 put / sell the $34 put to target ~15–20% downside with defined risk (max loss = premium). Size to 1–2% of portfolio; expected payoff 2–4x if negative discretionary trends or tariffs worsen.
• Short TSCO equity vs long WMT (equal dollar pair, 3–6 months): hedge macro beta and capture rotation into defensive, broad merchandisers if rural consumers cut discretionary spend. Expect 300–500bps relative outperformance; risk if rural consumption rebounds or price elasticity is lower than modeled.
• Contrarian long call spread on TSCO (12–18 months): buy the $55/$75 call spread to express a delayed margin recovery from Allivet + tariff relief with capped downside. Allocate 0.5–1% portfolio; payoff asymmetric (3–5x) if integration shows improving ARPU and gross margin.
• Overweight CHWY (6–12 months) vs TSCO exposure: increase exposure to a pure‑play pet channel that benefits if consumer pet health spend rotates to online/recurring purchases. Target 10–20% expected return; primary risk is TSCO executing Allivet integration faster than modeled.